Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;29(1):1-7.
doi: 10.1297/cpe.29.1. Epub 2020 Jan 9.

Pediatric drug development in Japan: Current issues and perspectives

Hiroyuki Saitou  1   2 , Daisaku Nakatani  2 , Akira Myoui  2 , Takuo Kubota  1 , Keiichi Ozono  1
Affiliations
Review

Pediatric drug development in Japan: Current issues and perspectives

Hiroyuki Saitou et al. Clin Pediatr Endocrinol. 2020.

Abstract

The number of clinical trials in Japan that aim to obtain regulatory approval for new drugs and devices has increased for adults, but not children. The following reasons have been proposed for this discrepancy: the wide range of ages from newborns to adolescents, requirements for many drug formulations, the difficulties associated with obtaining consent, and less profit for companies. The processes required to obtain regulatory approval for drugs and devices, particularly in the pediatric field, differ among Japan, Europe, and the United States (US). While clinical trials are not necessarily required for the development of new drugs or obtaining additional indications in Japan, laws in Europe and the US require clinical trials on children for newly developed drugs; however, pharmaceutical companies are entitled to a 6-mo extension for a patent when pediatric data are added to the attached documents for clinical trials. We herein discuss the current status of and issues associated with pediatric drug development, including clinical trials, in Japan as well as future perspectives.

Keywords: children; drug development; investigator-initiated clinical trials; regulations; sponsor-initiated clinical trials.

PubMed Disclaimer

References

    1. Nakagawa E. Clinical traials for children in Japan. Official Journal of the Japanese Society of Child Neurology 2013;45: 2.
    1. Study on securing and nurturing young physicians in pediatric obstetrics. http://wwwmhlwgojp/houdou/2005/06/h0628-2html.
    1. ICH-C11 CLINICAL INVESTIGATION OF MEDICINAL PRODUCTSOIN THE PEDIATRIC POPULATION. https://wwwpmdagojp/files/000156792pdf.
    1. Nakamura H, Ono S. Chapter 16. The Japanese perspective. In: Mulberg AE, editor. Pediatric drug development, 2nd ed. Wiley-Blackwell; 2013.
    1. Ito T, Urashihara H, Matsushima Y, Nakajima K, Kurokawa T. Mode of regulatory applications of drugs used off-label reviewed by the evalution committee on unapproved or off-labeled drugs with high medical needs. Jpn J Clin Pharmacol Ther 2015;46: 233–41.